Hasten Biopharmaceutic has acquired the commercial rights in China for Rocephin, a long-acting, broad spectrum cephalosporin antibiotic, from Swiss multinational healthcare company, Roche. Following the closing of the transaction earlier this year, there will be a transition period between Hasten and Roche.

Under the agreement, the China-based startup Hasten acquired Roche's China mainland rights for Rocephin, including the product's marketing authorisation and certain intellectual property, including trademarks. As a critical care product, Rocephin is a broad-spectrum antibiotic with strong brand value.

"The acquisition of Rocephin delivers strong commercial synergy with Hasten's current critical care portfolio in the Emergency Room, Intensive Care Unit, and Surgery departments, and positions us well to continue providing best-in-class treatments to benefit more patients," said Summer Xia, CEO of Hasten Biopharma.